ESHAP Salvage Therapy for Refractory and Relapsed Non-Hodgkin's Lymphoma: A Single Center Experience
Sang Hyoung Park, Shin Kim, Ok Bae Ko, Ja Eun Koo, Danbi Lee, Yong Pil Jeong, Jooryung Huh, Sung-Bae Kim, Sang We Kim, Jae-Lyun Lee, Cheolwon Suh
Korean J Intern Med. 2006;21(3):159-164. Published online 2006 Sep 30 DOI: https://doi.org/10.3904/kjim.2006.21.3.159
Citations to this article as recorded by 
Peripheral T-cell Lymphoma Presenting with Chylothorax
Seong Taeg Kim, Jaemin Jo, Jeong Rae Yoo, Miyeon Kim, Kyoung Hee Han, Jung Ho Kim, Sang Hoon Han
The Korean Journal of Medicine.2017; 92(1): 74. CrossRef
The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin’s lymp
Jiangzheng Zeng, Liangxia Yang, Fen Huang, Tao Hong, Zhihui He, Junhua Lei, Huamao Sun, Yanda Lu, Xinbao Hao
Cancer Chemotherapy and Pharmacology.2016; 78(4): 801. CrossRef
Modified ESHAP regimen for relapsed/refractory T cell lymphoma: a retrospective analysis
Yasunori Kogure, Akihide Yoshimi, Koki Ueda, Yasuhito Nannya, Motoshi Ichikawa, Fumihiko Nakamura, Mineo Kurokawa
Annals of Hematology.2015; 94(6): 989. CrossRef
Role of conventional salvage multiple-drug chemotherapy in relapsed and refractory aggressive non-Hodgkin lymphomas
PAOLO G. GOBBI, LARA VILLANO, DONATELLA POZZOLI, MANUELA BERGONZI
Oncology Letters.2010; 1(4): 679. CrossRef
Shortened and intensified MJMA: an effective salvage therapy for relapsed and refractory lymphomas and a strong mobilizer of PBSCs
P G Gobbi, F Valentino, P Lambelet, V Perfetti, G Bergamaschi, M Girino, G R Corazza
Bone Marrow Transplantation.2009; 44(1): 19. CrossRef